We have shown that American women with polycystic ovary syndrome (PCOS) have decreased glucose-stimulated release of a putative mediator of insulin action, D-chiro-inositol (DCI)-containing inositolphosphoglycan (DCI-IPG), and increased urinary clearance of DCI (uCl DCI ), which was associated with hyperinsulinemia. METHODS: DCI levels and the release of insulin and DCI-IPG during an oral glucose tolerance test (AUCs) were assessed in 27 Greek PCOS and 10 normal Greek women. RESULTS: PCOS women were heavier than controls (BMI 5 28.4 versus 23.7 kg/m 2 , P 5 0.05) with higher waist-to-hip ratios (WHR 5 0.78 versus 0.71, P 5 0.009) and increased free testosterone (P 5 0.048) and AUC insulin (P 5 0.04). In PCOS women, incremental AUC DCI-IPG was significantly decreased by 59% (2158 versus 5276% . min, P 5 0.01), even after correction for BMI and WHR. Finally, increased uCl DCI (r 5 0.35, P 5 0.04) and decreased AUC DCI-IPG (r 5 0.46, P 5 0.004) were significantly associated with hyperinsulinemia in all women together, even after correction for BMI and WHR (Ps 5 0.02 and 0.007), and regardless of PCOS status. CONCLUSIONS: Greek women, with or without PCOS, display increased uCl DCI and decreased AUC DCI-IPG in association with higher insulin levels but independent of adiposity. Increased clearance of inositols might reduce tissue availability of DCI and decrease the release of DCI-IPG mediator, which could contribute to insulin resistance and compensatory hyperinsulinemia in Greek women, as previously described in American women.
Introduction
The polycystic ovary syndrome (PCOS) is a common but still poorly understood disorder. It is defined by hyperandrogenism, chronic anovulation and/or polycystic ovaries (Zawadzki and Dunaif, 1992 ; The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004), and affects 6 -10% of women of childbearing age (Knochenhauer et al., 1998; Diamanti-Kandarakis et al., 1999; Asuncion et al., 2000) . PCOS is the most common endocrinopathy of women in this age group and is associated with an increased risk of developing hypertension, dyslipidemia, impaired glucose tolerance or Type 2 diabetes (Baillargeon et al., 2003; Cattrall and Healy, 2004) , and probably cardiovascular disease (Cibula et al., 2000; Solomon et al., 2002; Cattrall and Healy, 2004) .
Increasing evidence supports the central role of insulin resistance and/or increased insulin action in the syndrome's pathogenesis (Nestler, 1997; De Leo et al., 2003; Baillargeon 2005; Baillargeon and Carpentier, 2007) . Obese and lean women with PCOS manifest insulin resistance independent of fat mass (Dunaif et al., 1989) , and administration of insulin-sensitizing drugs, such as metformin (Diamanti-Kandarakis et al., 1998; Nestler et al., 1998; Baillargeon et al., 2004b; Nestler, 2008) , thiazolidinediones (Baillargeon et al., , 2004b Pesant and Baillargeon, 2006) and D-chiro-inositol (DCI) (Nestler et al., 1999; Iuorno et al., 2002; Gerli et al., 2003) , to both obese and lean women with the syndrome increases the frequency of ovulation and decreases circulating androgens.
Some actions of insulin may be effected by putative inositolphosphoglycan (IPG) mediators of insulin action (Saltiel, 1990; Romero and Larner, 1993) , and evidence suggests that a deficiency in a specific DCI-containing IPG (DCI-IPG) may contribute to insulin resistance in individuals with impaired glucose tolerance or Type 2 diabetes (Kennington et al., 1990; Asplin et al., 1993; Shashkin et al., 1997; Baillargeon et al., 2004a) . Furthermore, we have shown that metformin may improve the action of insulin in obese women with PCOS in part by improving insulin-mediated release of the DCI-IPG mediator (Baillargeon et al., 2004a) .
Our group has also recently demonstrated that high urinary clearance of DCI (uCl DCI ) is associated with insulin resistance and high insulin levels in American women, with or without PCOS, and that American PCOS women display reduced insulin-stimulated release of DCI-IPG . These results are consistent with a defect in tissue availability of DCI in American PCOS that may contribute to the insulin resistance of the syndrome. Moreover, our group (Nestler et al., 1999; Iuorno et al., 2002) and others (Gerli et al., 2003) have shown that oral administration of DCI to women with PCOS improves glucose tolerance while reducing circulating insulin in both obese (Nestler et al., 1999) and lean women with PCOS, and also decreases serum androgens and improves ovulatory function.
On the basis of these findings, we hypothesized that elevated uCl DCI is associated with insulin resistance not only in American women, with or without PCOS, but also in a population with a different ethnic and geographic origin, such as Greek women. To assess this hypothesis, we studied women with PCOS and normal women from the region of Athens, in Greece, and assessed circulating DCI and 24 h uCl DCI , release of insulin and DCI-IPG during an oral glucose tolerance test (OGTT), and insulin sensitivity by the minimal model technique.
Research design and methods

Subjects
Twenty-seven women with PCOS and 10 normal controls were evaluated at the Endocrine unit, first department of Medicine, Laiko Hospital of the University of Athens Medical School, Athens, Greece. PCOS was defined by oligo-amenorrhea ( 8 menstrual periods in the previous year) and hyperandrogenism (hirsutism, acne or elevated serum total or free testosterone concentration); while hyperprolactinemia, thyroid dysfunction and late-onset adrenal hyperplasia were excluded by the appropriate tests. Ovarian ultrasounds were not performed such that our more stringent criteria met both 1990 NIH and 2003 Rotterdam conferences diagnostic criteria (Zawadzki and Dunaif, 1992 ; The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004). However, based on these criteria, a woman could have been classified as having PCOS even if her testosterone levels were normal, providing that she had hyperandrogenic signs.
Normal women were recruited from the endocrine outpatient clinic of first department of Medical Laiko Hospital. They were regularly followed-up for thyroid problems, such as simple goiters or thyroid nodules and were euthyroid without medication. They had regular menstrual cycles, absence of acne and hirsutism, normal androgen levels and glucose tolerance, and did not have any history of gestational diabetes or family history of a first-degree relative with diabetes. They were free of diabetes, hypertension, dyslipidemia, or kidney or heart diseases. All women were 18-40 years old and none took oral contraceptives or any medication known to affect insulin sensitivity for at least 2 months prior to study. The study has been approved by the institutional review board of Laiko Hospital and Virginia Commonwealth University, and each woman gave written informed consent.
Study protocol
Because DCI may be ingested as part of a diet high in legumes or fruits, the women were given instructions for a balanced mixed diet to be followed for at least 3 days prior to the start of the study. PCOS women were studied during the equivalent of the follicular phase of the menstrual cycle, as confirmed by a serum progesterone 6.5 nmol/l (2 ng/ml). Normal women were studied during the mid-follicular phase of the menstrual cycle (Days 5-9), which most closely approximates the hormonal milieu of anovulatory women with PCOS.
On the first day, fasting baseline laboratories and a 2-h OGTT with 75 g of dextrose were performed. During the OGTT, blood samples were collected every 15 min for determination of serum glucose and insulin concentrations, and serum DCI-IPG bioactivity was determined every 30 min. (Hanson et al., 2000) . Women were then instructed to collect all their urine for 24 h before the next visit.
On the second day, after a 12-h overnight fast, insulin sensitivity was measured by the frequent sampling intravenous glucose tolerance test (FSIVGTT) technique as described by Bergman (Bergman et al., 1981; Yang et al., 1987; Bergman, 1989) . At zero time, 300 mg/kg of dextrose was administered intravenously and 0.03 U/kg insulin was administered intravenously 20 min later. A total of 27 blood samples for determination of insulin and glucose were collected over the 3-h duration of the protocol. Data were analysed with the Minimal Model Identification Software (MINMOD # , version 6.02, 2004) (Pacini and Bergman, 1986) , which yields quantitative determination of glucose-mediated disappearance of glucose (S g , or glucose effectiveness), tissue insulin sensitivity (S i ), acute insulin response to glucose (AIR g ) and disposition index (DI ¼ S i Â AIR g ).
Laboratory assays
Blood samples were centrifuged immediately, and sera were stored at 2708C until they were shipped all at once in dry ice to Richmond, and then stored again at 2708C until assayed. All hormones were assayed as previously described (Nestler et al., 1989 (Nestler et al., , 1991 (Nestler et al., , 1994 . Blood glucose and insulin levels were determined by the core laboratory of the General Clinical Research Center of the Virginia Commonwealth University Health System. All other analytes were assayed in Dr Nestler's laboratory at Virginia Commonwealth University. Serum free testosterone was calculated by the method of Sodergard et al. (1982) using a serum albumin concentration of 40 g/l. To avoid inter-assay variation, all samples were analysed in duplicate in a single assay for each hormone. The intra-assay coefficient of variation for the insulin was 5.5%, and was less than 10% for all steroid hormone assays.
DCI and MYO-inositol analyses
Plasma and urinary inositol concentrations were determined by gas chromatography and mass spectrometry. [ 2 H 6 ]Racemic chiro-inositol and [ 2 H 6 ]myo-inositol were added to plasma or urine as internal standards. The samples were then purified, derivatized with pentafluoropropionic anhydride, separated on a Chirasil-Val capillary column (Alltech, State College, PA, USA), and analysed in negative ion chemical ionization mode on an HP 5973 mass spectrometer (Agilent Technologies, Palo Alto, CA, USA) with methane as the reagent gas, as previously reported (Ostlund et al., 1993) . Twenty-four hour urinary clearance was calculated by dividing 24 h urinary excretion by plasma concentration.
DCI containing inositolphosphyglycans (DCI-IPG) insulin mediator bioactivity assay DCI-IPG mediator was isolated from serum as previously described (Baillargeon et al., 2004a) . To date, it has not been possible to measure the content of extracted DCI-IPG because its structure and exact mass are unknown, and no specific antibody suitable for an immunoassay has been developed. Therefore, DCI-IPG mediator bioactivity was determined using the specific activation of pyruvate dehydrogenase (PDH) phosphatase, as previously validated in women with PCOS and described in detail (Baillargeon et al., 2004a) . The inter-assay coefficient of variation of the bioassay was 17.4%. The PDH activity intra-assay coefficient of variation was 6.7%. Coefficients of variation of the entire method (extraction and assay) were 10.7 and 8.5%, respectively, for the absolute values of basal and peak DCI-IPG bioactivity.
In order to adjust for variation in basal PDH activity from one assay to the other, and therefore from subject to subject, the water-blank activity was subtracted from the bioactivity of DCI-IPG released into serum during OGTT, which was then expressed as the percentage of its bioactivity at baseline (0 min).
Statistical analyses
We analysed the response of serum insulin concentrations and relative bioactivities of DCI-IPG to the oral administration of glucose by calculating the areas under the respective response curves (AUC) by the trapezoidal rule. Results not normally distributed, based on the Normal Quintile Plot, were log-transformed for all statistical analyses and reported back-transformed in their original units. All results are reported as means with 95% confidence intervals. A value of Ps , 0.05 were considered significant. All analyses were performed using JMP # 7.0 software (SAS Institute, Cary, NC, USA). The primary variables of interest for this study were 24 h uCl DCI and insulin-stimulated release of the DCI-IPG insulin mediator (AUC DCI-IPG ). Variable comparisons between groups were made with Student's two-tailed t-test, and equalities of variances were tested with the Brown-Forsythe test. For comparisons with unequal variances, Ps of Welch ANOVA tests were reported, as indicated. Correlation analysis was performed using Pearson's correlation test. With 27 PCOS and 10 control women, this study has 70% power to detect the same group difference in uCl DCI than the difference we previously observed in American PCOS women (1.75 on log e scale) , considering the same common standard deviation (1.85 on log e scale).
Since BMI and waist-to-hip ratio (WHR) differed between groups (see Table I ), all comparisons and correlations were corrected for both variables using multiple linear regression analyses. Possible interactions between BMI and PCOS status for DCI or DCI-IPG parameters were also tested because a significant interaction with uCl DCI was found in American women . However, no interaction was found in the present study.
In order to determine the best models to predict our primary variables of interest, manual stepwise multiple linear regression analyses were performed. All variables reported in Table II that were associated with uCl DCI or AUC DCI-IPG (P 0.10) were entered successively in the model based on the next best P-value (forward method); except for 24 h urinary excretions, which were collinear with clearances, AUC DCI-IPG -AUC insulin ratio, which was collinear with AUC insulin , as well as DI and IGI 15 , which were redundant with AIR g . All possible interactions with variables previously kept in the model were also included at each step. Thereafter, parameters that did not contribute significantly to the model were excluded (partial P . 0.01 for interactions). We also preformed a stepwise analysis to determine the best independent predictors of AUC insulin , using the same method.
Since this study used the same protocol and laboratory methodologies as our previously published study , it was possible to pool data of both studies in one dataset and to test correlations between our primary variables of interest and AUC insulin for all women (Fig. 1) . Interactions between AUC insulin and Greek or American origin were also tested.
Results
Clinical and biochemical characteristics
Women with PCOS did not differ significantly from normal control women with respect to age, systolic blood pressure and diastolic blood pressure (Table I ). However, their BMI tended to be higher (P ¼ 0.05) and their WHR was significantly higher (P ¼ 0.009).
Calculated free testosterone levels were significantly increased by more than 75% in women with PCOS as compared to control women (P ¼ 0.048). This difference was no longer significant after correction for BMI and WHR. Although fasting insulin levels were 50% higher in PCOS women compared with control women, the difference was not significant (P ¼ 0.21), whereas areas under the insulin curves during OGTT (AUC insulin ) were 65% higher (P ¼ 0.04) in PCOS women compared with normal controls. AUC insulin was no longer significantly different between groups after correction for BMI and WHR. IGI 15 was not calculable (negative result) in two PCOS women and was not significantly different between groups. Regarding the fitting of FSIVGTT data, the MINMOD program did not generate S i result for one PCOS women and AIR g for three PCOS women. Accordingly, DI (S i ÂAIR g ) was unavailable for four PCOS women, which reduced the power of this analysis. Although S i was reduced by 44% in PCOS women, this difference was only borderline significant (P ¼ 0.07). S g , AIR g and DI were not significantly different between groups, although there was a trend for lower mean DI in PCOS women (decreased by 30%, P ¼ 0.43).
DCI and MYO-inositol (MYO) metabolism
Plasma concentrations of DCI and 24 h urinary excretion and clearance of DCI were comparable between PCOS women and normal controls (Table I ). Corresponding parameters were also similar between groups for MYO. However, AUC DCI-IPG was significantly reduced in PCOS women as compared with controls (P ¼ 0.01), even after correction for BMI and WHR (P ¼ 0.01). Incremental AUC DCI-IPG , i.e. AUC DCI-IPG above baseline, was decreased by almost 60% in PCOS women compared with controls. Finally, the ratio of AUC DCI-IPG to AUC insulin was reduced by half in women with PCOS (P ¼ 0.02), which remained significant after correction for BMI and WHR (P ¼ 0.047).
Correlation between hyperinsulinemia (AUC insulin ) and uCl DCI ) or insulin-stimulated release of DCI-IPG (AUC DCI-IPG ) When all women were included, there was a direct correlation between AUC insulin and uCl DCI that was statistically significant (Fig. 1A: r ¼ 0.35, P ¼ 0.04). The negative correlation between AUC insulin and AUC DCI-IPG was even more robust and significant (Fig. 1B: r ¼ 0.46, P ¼ 0.004). These associations persisted after adjustment for differences both in BMI and WHR (Ps ¼ 0.02 and 0.007, respectively). Furthermore, no interaction was found between PCOS status and AUC insulin (P ¼ 0.12 for uCl DCI and P ¼ 0.34 for AUC DCI-IPG ), such that these correlations were not driven by the effects in only one of the groups. When assessing these correlations within each group, AUC insulin was positively associated with uCl DCI both in PCOS (r ¼ 0.40, P ¼ 0.04) and normal women (r ¼ 0.64, P ¼ 0.04). There were also negative correlations between AUC insulin and AUC DCI-IPG within each group (r ¼ 0.33 for PCOS and r ¼ 0.57 for controls), but they were not significant in these sub-group analyses (P ¼ 0.08 and 0.09, respectively).
After combining the data from the present population with the previously published data from Richmond, Virginia, a total of 86 women were analysed, i.e. 50 women with PCOS (27 from Greece and 23 from USA) and 36 normal controls (10 from Greece and 26 from USA). Using this database and analysing all the women together (n ¼ 86), a significant positive correlation persisted between AUC insulin and uCl DCI (Fig. 1C: r ¼ 0.32, P ¼ 0.003) and a negative correlation persisted between AUC insulin and AUC DCI-IPG (Fig. 1D : r ¼ 20.31, P ¼ 0.004). The association between hyperinsulinemia and increased uCl DCI remained significant after adjustment for BMI and WHR (P ¼ 0.002), but this was not the case for AUC DCI-IPG (P ¼ 0.06). There was no interaction between AUC insulin and PCOS status for either analysis, as well as between AUC insulin and Greek or American origin. Therefore, these significant correlations are valid regardless of women's origin and PCOS status.
Stepwise multivariate analyses As described in the Statistical analyses section, the best models predicting our primary variable of interests, i.e. uCl DCI and AUC DCI-IPG , were determined using manual stepwise multivariate analyses. Variables associated with uCl DCI with P 0.10 were pDCI (P ¼ 0.004), uCl MYO (P ¼ 0.009), AUC insulin (P ¼ 0.04), pMYO (P ¼ 0.09) and AUC DCI-IPG (P ¼ 0.10). Using these independent variables, the stepwise analysis revealed that the best factors independently associated with DCI urinary clearance were plasmatic DCI levels (partial P ¼ 0.003) and MYO urinary clearance (partial P ¼ 0.006), which explained 37.6% of the variance of uCl DCI (R 2 ¼ 0.376, P , 0.001). Variables associated with AUC DCI-IPG with P 0.10 were AUC insulin (P ¼ 0.004), PCOS status (P ¼ 0.01), S g (P ¼ 0.07), pDCI (P ¼ 0.08) and uCl DCI (P ¼ 0.10). After stepwise analysis, the only independent variable significantly associated with AUC DCI-IPG was AUC insulin , which explained 21.6% of the variability of AUC DCI-IPG (R 2 ¼ 0.216, P ¼ 0.004). Since we determined that our primary variables of interest are significantly associated with hyperinsulinemia, we sought to determine if parameters of inositols metabolism were significant predictors of AUC insulin , independently from classical determinants of hyperinsulinemia that were assessed in our study. Thus, a third stepwise analysis was performed. Variables associated with AUC insulin during univariate analyses (P 0.10) are reported in Table II , and the final model in Table III . The total number of subjects included in the final model is 36 due to unavailable S i in one PCOS women. As shown, the best parameters significantly associated with AUC insulin are insulin sensitivity (S i , partial P , 0.001), plasmatic MYO levels (partial P ¼ 0.008), MYO urinary clearance (partial P ¼ 0.01) and AUC DCI-IPG (partial P ¼ 0.02), which explained 71.4% of the variance of AUC insulin (R 2 ¼ 0.714, P , 0.001). Of note, inositols and DCI-IPG parameters increased the predictive precision of the model from 34.9%, when considering S i alone, to 71.4%, i.e. an absolute increase of 36.5%.
Discussion
This study was designed to test the hypothesis that Greek women with or without PCOS would exhibit alterations in the metabolism of DCI and insulin-stimulated release of the putative insulin mediator DCI-IPG similar to those previously observed in American PCOS women and controls . Direct comparisons of both populations are possible because identical protocols and laboratory techniques were used. In Greek PCOS women, glucose-stimulated insulin levels (AUC insulin ) were significantly increased by 65% compared with normal Greek women, which reflects mainly compensatory hyperinsulinemia resulting from insulin resistance. Concomitantly, insulin-stimulated release of bioactive DCI-IPG (incremental AUC DCI-IPG ) was reduced by 60%. Moreover, this last analysis remained significant after correction for BMI and WHR. Thus, these findings support a role for defective DCI-IPG insulin mediator activity in the pathophysiology of PCOS, which is independent of adiposity and most likely related to compensatory hyperinsulinemia. Correlations between glucose-stimulated insulin levels (AUC insulin ) and uCl DCI (A) or glucose-stimulated DCI-containing inositolphosphoglycan (AUC DCI-IPG ) bioactivity (B) in Greek women with PCOS ( †) and Greek control women (W). After pooling data from this study and a previously published PCOS study ), C and D illustrate correlations between AUC insulin and uCl DCI (C) or AUC DCI-IPG (D) in Greek PCOS ( †) and control (W) women, as well as American PCOS (B) and control (A) women. Results are represented back transformed in their original units, on log scales. ‡ P ¼ 0.02 or § P 0.007 when adjusted for BMI and WHR Greek PCOS women display altered DCI metabolism
Importantly, this study also demonstrated that, when all Greek women were analysed together, hyperinsulinemia was significantly associated with increased 24 h uCl DCI and reduced AUC DCI-IPG , even after correction for adiposity. After combining primary data from this study with our previously published study in American women , these associations remained highly significant. Finally, there was no interaction with origin or PCOS status. Therefore, these findings suggest that alterations in the metabolism of DCI and DCI-IPG are related to compensatory hyperinsulinemia in all women, regardless of adiposity, origin and PCOS status. However, DCI and DCI-IPG metabolism was not related to acute insulin response (IGI 15 and AIR g ) and beta-cell function (DI).
Another important finding of our study is that parameters of inositols metabolism were the best independent predictors of high insulin levels, together with insulin resistance. Moreover, inositols and measures of DCI-IPG release increased the precision of predicting AUC insulin by an additional 43% over the contribution of insulin sensitivity alone; and only 29% of the variability of AUC insulin was explained by other unknown factors. This supports an important role of inositols metabolism and the DCI-IPG insulin mediator in the expression of compensatory hyperinsulinemia in Greek women.
However, it was unexpected that MYO plasma levels and urinary clearance (uCl MYO ) would be more strongly associated with higher insulin concentrations than corresponding parameters of DCI. Indeed, MYO metabolism was not altered in American PCOS women and was not correlated with insulin sensitivity or insulin levels . This new finding may be explained in part by high correlations between MYO and DCI parameters in Greek women, such that the best predictors of uCl DCI were uCl MYO and plasmatic DCI levels. Thus, it is possible that the same renal defect affects urinary clearance of both inositols in Greek hyperinsulinemic women. Accordingly, DCI may still be the inositol implicated in the development of insulin resistance and compensatory hyperinsulinemia, but alteration in MYO clearance may be more apparent simply because the amounts of MYO in plasma and tissues largely exceed the amounts of DCI. It is however unknown why MYO and DCI clearance correlate in Greek but not in American women. This might be due to differences in diet content of inositols, although this variable was not assessed in our study.
Nonetheless, it remains possible that the metabolism of MYO also plays a role in the hyperinsulinemia of Greek women, resulting in less availability of MYO to tissues. Since it has been shown in tissues that [ (Pak et al., 1993) , decreased MYO availability would result in less DCI substrate for the generation of the DCI-IPG insulin mediator. A possible role of MYO in the pathophysiology of PCOS in women of Mediterranean origin is further supported by the results of a recent randomized-controlled trial in 40 lean Italian PCOS patients undergoing ovulation induction for ICSI (Papaleo et al., 2007b) . This trial demonstrated that oral administration of MYO reduced r-FSH dose and duration, estradiol levels at hCG injection and the number of oocytes of poor quality in PCOS women. Another uncontrolled prospective study in 25 infertile Italian PCOS women found that oral MYO increases spontaneous ovarian activity and fertility (Papaleo et al., 2007a) .
Surprisingly, 24 h uCl DCI and other inositols did not differ in Greek PCOS women compared with Greek controls, which contrasts with our previous findings in American PCOS women . One possible explanation is that American women were substantially more obese, i.e. the mean BMI for American women was 33.9 versus 28.4 kg/m 2 for Greek women. Indeed, sub-group analyses in American PCOS women revealed that DCI urinary clearance was increased only in PCOS women whose BMI was !30 kg/m 2 , and was similar in PCOS and normal women with BMI , 30 kg/m 2 . Furthermore, Greek PCOS women were substantially less insulinresistant, less hyperinsulinemic and less hyperandrogenic than American PCOS women. Thus, a milder clinical syndrome in Greek women might explain the lack of difference in urinary DCI clearance between Greek PCOS and normal women. Finally, this discrepancy might just result from the small number of Greek control women.
On the basis of these results, we propose that higher renal clearance of inositols tends to decrease plasma inositols levels and, ultimately, intra-tissue generation of DCI-IPG. Decreased insulin-stimulated release of DCI-IPG, in turn, contributes to lower insulin sensitivity and a resulting compensatory hyperinsulinemia. Variability in urinary clearance of inositols might be due to obesity, lifestyle, or PCOS-related genetic and/or other genetic factors. Thus, renal clearance of inositols probably contributes to the variability of insulin sensitivity in women. Although it might not be a major contributor to insulin resistance in the general population, this contribution might be more important in some individuals, such as PCOS women.
Another possible scenario is that compensatory hyperinsulinemia itself induces a defect that increases renal clearance of inositols. It is also possible that both scenarios are valid and present in hyperinsulinemic women, causing a 'vicious cycle' whereby insulin resistance and compensatory hyperinsulinemia are amplified in these women through the induction of a defect in renal clearance of inositols.
Despite interesting and highly significant results, even after correction for adiposity, there are limitations to our study. First, the number of Greek normal controls is relatively small. Therefore, it was not possible to ascertain whether non-significant differences between Greek PCOS and control were due to random distribution instead of true physiological differences. This also holds true for the absence of a modifying effect of PCOS status on reported correlations in Greek women alone. Second, since only PCOS and normal women were studied, inference to other populations would be speculative. Furthermore, because of the cross-sectional design of this study, it is unknown if significant correlations reflect causative links or only associations. Also, cases and controls were not matched for adiposity (e.g. BMI), such that an effect of obesity cannot be completely excluded. Indeed, adjusting for BMI, as we did, assumes linear relationships, but it may not be the case. Finally, our control group was recruited from an endocrine clinic and might not be entirely representative of the community.
In conclusion, results of the present study demonstrated that hyperinsulinemic Greek women with or without PCOS displayed increased urinary clearance of inositols and decreased insulin-stimulated release of bioactive DCI-IPG, independently of adiposity. Thus, increased inositols clearance and reduced DCI-IPG generation might contribute to insulin resistance and compensatory hyperinsulinemia in Greek as well as American women. These findings offer potential mechanisms for previously reported benefits of DCI or MYO oral administration on metabolic and clinical derangements in PCOS women (Nestler et al., 1999; Iuorno et al., 2002; Gerli et al., 2003; Papaleo et al., 2007a,b) . Whether abnormalities of DCI metabolism and DCI-IPG release are specific to PCOS or relevant to other disorders characterized by insulin resistance is still unknown.
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